12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vismodegib: Interim Phase II data

Interim data from 29 evaluable patients who completed an average of 6 months of treatment in an 18-month, double-blind, U.S. Phase II trial showed that once-daily 150 mg oral vismodegib significantly reduced the rate of new BCCs per month (0.07 vs. 1.74, p<=0.0001) and the cumulative diameter of existing BCCs vs. placebo (24 vs. 3 cm, p=0.006). Based on the results, the study's DSMB recommended ending the placebo arm of the...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >